GlassScriptPhysician profile
Marc Vanderleeden
NPI 1801883194
$8,255.90
in general payments reported to CMS, 2019-2025
47 companies · $989 in 2025
The $989 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $761 · 2021: $1,125 · 2022: $1,180 · 2023: $1,406 · 2024: $1,320 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,715.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,526.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,168.27 | 2019-2025 | Repatha, Evenity, Prolia |
| Novo Nordisk INC | $830.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $562.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $444.46 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.51 | 2020-2025 | Jardiance, Tradjenta |
| Antares Pharma, INC. | $268.02 | 2019-2025 | Xyosted |
| Janssen Pharmaceuticals, INC | $265.40 | 2019-2022 | |
| Abbott Laboratories | $212.53 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $203.82 | 2023-2025 | Synthroid |
| Merck Sharp & Dohme LLC | $167.61 | 2019-2022 | |
| Amarin Pharma, INC. | $165.01 | 2020-2021 | |
| Pfizer INC. | $148.38 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $148.20 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $145.35 | 2019-2025 | Tymlos |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Vanderleeden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.